Your browser doesn't support javascript.
loading
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Jaeger, Hans; Overton, Edgar T; Richmond, Gary; Rizzardini, Giuliano; Andrade-Villanueva, Jaime Federico; Mngqibisa, Rosie; Hermida, Antonio Ocampo; Thalme, Anders; Belonosova, Elena; Ajana, Faïza; Benn, Paul D; Wang, Yuanyuan; Hudson, Krischan J; Español, Carlos Martín; Ford, Susan L; Crauwels, Herta; Margolis, David A; Talarico, Christine L; Smith, Kimberly Y; van Eygen, Veerle; Van Solingen-Ristea, Rodica; Vanveggel, Simon; Spreen, William R.
Affiliation
  • Jaeger H; MVZ Karlsplatz, HIV Research and Clinical Care Centre, Munich, Germany. Electronic address: dhanjaeger@hotmail.com.
  • Overton ET; 1917 Clinic, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Richmond G; Nova Southeastern University, Fort Lauderdale, FL, USA.
  • Rizzardini G; Fatebenefratelli Sacco Hospital, Milan, Italy; School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
  • Andrade-Villanueva JF; Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico.
  • Mngqibisa R; Durban International Clinical Research Site, Enhancing Care Foundation, Wentworth Hospital, Durban, South Africa.
  • Hermida AO; Department of Internal Medicine, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.
  • Thalme A; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Belonosova E; Regional Center for Prevention and Treatment of Acquired Immunodeficiency Syndrome and Infectious Diseases, Orel, Russia.
  • Ajana F; Centre Hospitalier de Tourcoing, Tourcoing, France.
  • Benn PD; ViiV Healthcare, Brentford, UK.
  • Wang Y; GlaxoSmithKline, Collegeville, PA, USA.
  • Hudson KJ; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Español CM; GlaxoSmithKline, Brentford, UK.
  • Ford SL; GlaxoSmithKline, Research Triangle Park, NC, USA.
  • Crauwels H; Janssen Research & Development, Beerse, Belgium.
  • Margolis DA; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Talarico CL; ViiV Healthcare, Research Triangle Park, NC, USA.
  • Smith KY; ViiV Healthcare, Research Triangle Park, NC, USA.
  • van Eygen V; Janssen Research & Development, Beerse, Belgium.
  • Van Solingen-Ristea R; Janssen Research & Development, Beerse, Belgium.
  • Vanveggel S; Janssen Research & Development, Beerse, Belgium.
  • Spreen WR; ViiV Healthcare, Research Triangle Park, NC, USA.
Lancet HIV ; 8(11): e679-e689, 2021 11.
Article in En | MEDLINE | ID: mdl-34648734
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / Anti-HIV Agents Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Adult / Female / Humans / Newborn Language: En Journal: Lancet HIV Year: 2021 Document type: Article Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / Anti-HIV Agents Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Adult / Female / Humans / Newborn Language: En Journal: Lancet HIV Year: 2021 Document type: Article Country of publication: Netherlands